Eli Lilly disclosed that a combination therapy pairing its amylin-targeting compound eloralintide with its blockbuster drug tirzepatide produced greater weight loss than either treatment alone in a mid-stage clinical trial. The pharmaceutical giant said the results support moving the combo into late-stage testing, with Phase 3 trials slated to begin by year-end. The announcement extends Lilly's push to defend its lead in the fast-growing obesity drug market against rival Novo Nordisk, as both companies race to develop more effective and better-tolerated treatments.
Tirzepatide, sold under the brand names Mounjaro and Zepbound, has already become one of the best-selling drugs in Lilly's portfolio, and pairing it with an amylin analog like eloralintide represents the company's latest attempt to boost efficacy by targeting multiple metabolic pathways at once. Amylin drugs work by mimicking a hormone that helps regulate appetite and blood sugar, and combining that mechanism with tirzepatide's dual-action approach could set a new bar for the obesity treatment category if the Phase 3 data holds up.
The update lands in a market session showing broad but uneven gains. The S&P 500 rose 0.34% to 7,697.07, trading within striking distance of its 52-week high of 7,816.70. The Nasdaq Composite outperformed with a 0.79% advance to 27,008.48, sitting just shy of its own 52-week peak near 27,288.79, reflecting continued investor appetite for growth and health-care innovation stories. The Dow Jones Industrial Average lagged, slipping 0.28% to 51,207.66, a sign that gains were concentrated outside the blue-chip industrial and financial names that dominate that index.
For Lilly, the stakes extend well beyond one trial readout. The obesity drug market has drawn intense competitive spending as pharmaceutical companies chase a patient population that analysts expect to keep expanding through the decade. Positive mid-stage data doesn't guarantee success in Phase 3, where larger patient populations and longer follow-up periods often surface side effects or diminishing efficacy that weren't apparent in smaller trials. Still, an amylin-tirzepatide combination that outperforms tirzepatide alone would give Lilly a potential next-generation product to sell alongside its existing lineup, extending its commercial runway before patent and competitive pressures intensify.
Investors will now watch for enrollment details and timelines on the Phase 3 program, which won't produce data for at least a year or more given typical trial durations. In the meantime, the broader health-care and biotech sector may continue to draw attention as other companies with obesity-drug candidates in development look to keep pace with Lilly's progress.